Search: onr:"swepub:oai:DiVA.org:uu-24928" >
Five-year follow-up...
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
-
Druker, Brian J. (author)
-
Guilhot, Francois (author)
-
O'Brien, Stephen G. (author)
-
show more...
-
Gathmann, Insa (author)
-
Kantarjian, Hagop (author)
-
Gattermann, Norbert (author)
-
Deininger, Michael W. N. (author)
-
Silver, Richard T. (author)
-
Goldman, John M. (author)
-
Stone, Richard M. (author)
-
Cervantes, Francisco (author)
-
Hochhaus, Andreas (author)
-
Powell, Bayard L. (author)
-
Gabrilove, Janice L. (author)
-
Rousselot, Philippe (author)
-
Reiffers, Josy (author)
-
Cornelissen, Jan J. (author)
-
Hughes, Timothy (author)
-
Agis, Hermine (author)
-
Fischer, Thomas (author)
-
Verhoef, Gregor (author)
-
Shepherd, John (author)
-
Saglio, Giuseppe (author)
-
Gratwohl, Alois (author)
-
Nielsen, Johan L. (author)
-
Radich, Jerald P. (author)
-
- Simonsson, Bengt (author)
- Uppsala universitet,Institutionen för medicinska vetenskaper,Blodsjukdomar
-
Taylor, Kerry (author)
-
Baccarani, Michele (author)
-
So, Charlene (author)
-
Letvak, Laurie (author)
-
Larson, Richard A. (author)
-
show less...
-
(creator_code:org_t)
- 2006
- 2006
- English.
-
In: New England Journal of Medicine. - 0028-4793 .- 1533-4406. ; 355:23, s. 2408-2417
- Related links:
-
https://urn.kb.se/re...
-
show more...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- BACKGROUND: The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-ABL tyrosine kinase. Imatinib inhibits this kinase, and in a short-term study was superior to interferon alfa plus cytarabine for newly diagnosed CML in the chronic phase. For 5 years, we followed patients with CML who received imatinib as initial therapy. METHODS: We randomly assigned 553 patients to receive imatinib and 553 to receive interferon alfa plus cytarabine and then evaluated them for overall and event-free survival; progression to accelerated-phase CML or blast crisis; hematologic, cytogenetic, and molecular responses; and adverse events. RESULTS: The median follow-up was 60 months. Kaplan-Meier estimates of cumulative best rates of complete cytogenetic response among patients receiving imatinib were 69% by 12 months and 87% by 60 months. An estimated 7% of patients progressed to accelerated-phase CML or blast crisis, and the estimated overall survival of patients who received imatinib as initial therapy was 89% at 60 months. Patients who had a complete cytogenetic response or in whom levels of BCR-ABL transcripts had fallen by at least 3 log had a significantly lower risk of disease progression than did patients without a complete cytogenetic response (P<0.001). Grade 3 or 4 adverse events diminished over time, and there was no clinically significant change in the profile of adverse events. CONCLUSIONS: After 5 years of follow-up, continuous treatment of chronic-phase CML with imatinib as initial therapy was found to induce durable responses in a high proportion of patients. (ClinicalTrials.gov number, NCT00006343 [ClinicalTrials.gov].)
Keyword
- MEDICINE
- MEDICIN
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Druker, Brian J.
-
Guilhot, Francoi ...
-
O'Brien, Stephen ...
-
Gathmann, Insa
-
Kantarjian, Hago ...
-
Gattermann, Norb ...
-
show more...
-
Deininger, Micha ...
-
Silver, Richard ...
-
Goldman, John M.
-
Stone, Richard M ...
-
Cervantes, Franc ...
-
Hochhaus, Andrea ...
-
Powell, Bayard L ...
-
Gabrilove, Janic ...
-
Rousselot, Phili ...
-
Reiffers, Josy
-
Cornelissen, Jan ...
-
Hughes, Timothy
-
Agis, Hermine
-
Fischer, Thomas
-
Verhoef, Gregor
-
Shepherd, John
-
Saglio, Giuseppe
-
Gratwohl, Alois
-
Nielsen, Johan L ...
-
Radich, Jerald P ...
-
Simonsson, Bengt
-
Taylor, Kerry
-
Baccarani, Miche ...
-
So, Charlene
-
Letvak, Laurie
-
Larson, Richard ...
-
show less...
- Articles in the publication
-
New England Jour ...
- By the university
-
Uppsala University